Categories | Inventors

Inhibition of DNA polymerase kappa and its structural homologs and orthologs to augment chemotherapeutic or antimicrobial effectiveness


OHSU # 1165

Technology Overview:

Inhibition of DNA Polymerase Kappa

Researchers at Oregon Health & Science University have identified human DNA polymerase kappa (pol κ) as essential for repairing DNA containing interstrand crosslinks (ICLs) and the use of inhibitors of DNA polymerase, such as pol κ for the treatment of hyperproliferative, autoimmune or infectious disease.  Additionally, pol κ inhibitors may be used to enhance the efficacy of ICL-inducing agents since the mechanism of action of a number of chemotherapeutic and antimicrobial agents is the induction of ICLs. In collaboration with the National Chemical Genomics Center at the NIH, Dr. Lloyd developed a novel assay for ultra high throughput screening systems and has identified inhibitors of pol κ that range in activity from low μM to low-mid nM (e.g. 100 – 500 nM); an ideal range for lead selection and initiation of lead optimization.

Patent Filed

Investigator: R. Stephen Lloyd, PhD

If interested in learning more, please contact Technology Transfer and Business Development ( and reference Tech Id No. 1165.



IssuedUnited States8,715,927


For more information, contact:

Anne Carlson
Technology Development Manager